Dezima Pharma secures $18.6m for CETP inhibitor development
The company received €9.8m capital in a Series A funding round, led by Forbion Capital Partners (NL) and BioGeneration Ventures (NL), with participation from New Science Ventures (USA)
Anixa Biosciences has secured a patent from the Korean Ministry of Intellectual Property (MOIP) for its breast cancer vaccine technology.
Under the partnership, Crystal Pharmatech combines its expertise with Particle Sciences advanced drug delivery solutions compounds to offer clients an optimal solution for developing low solubility pharmaceutical compounds.